CNBC Pro: Morgan Stanley says this global biotech stock could soar 398% in the next year
Analysts at Morgan Stanley think one global biotech company's stock could soar 398% in the next year. The company's latest regenerative medicine has completed phase 2 trials in Japan and U.S. and is awaiting final approval.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: